Risk Assessments for Breast and Ovarian Cancer Syndrome
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Enhanced Risk Assessments for Breast and Ovarian Cancer Syndrome?
The effectiveness of Enhanced Risk Assessments for Breast and Ovarian Cancer Syndrome is supported by comprehensive programs that include genetic testing, counseling, and long-term follow-up for high-risk patients, as recommended by the Department of Defense Familial Breast/Ovarian Cancer Research Project. These programs help in identifying and managing patients at high risk, which can lead to better personalized care and potentially improved outcomes.12345
Is the genetic cancer risk assessment for hereditary breast and ovarian cancer syndrome safe for humans?
How does the treatment Enhanced Risk Assessments differ from other treatments for breast and ovarian cancer syndrome?
Enhanced Risk Assessments focus on personalized risk prediction using models that consider genetic factors like BRCA mutations and family history, which is different from standard treatments that may not tailor prevention strategies as precisely. This approach helps in making informed decisions about preventive measures, such as the use of medications like Tamoxifen, based on individual risk profiles.56101112
What is the purpose of this trial?
This clinical trial evaluates the impact of enhanced risk assessments on knowledge, perceptions, and decisional conflict about cancer prevention in women with a BRCA1 or BRCA2 mutation. BRCA1/2 mutation carriers have a much higher risk of developing breast and ovarian cancer. Due to the high risk of cancer, mutation carriers are provided guidelines on more intensive screening and preventative surgeries such as bilateral mastectomy and bilateral salpingo-oophorectomy. Doctors want to learn if a more personalized risk assessment impacts the patients' risk perceptions and comfort with decision-making around cancer prevention behaviors.
Research Team
Amanda E Toland
Principal Investigator
Ohio State University Comprehensive Cancer Center
Eligibility Criteria
This trial is for women with a BRCA1 or BRCA2 mutation, which greatly increases their risk of breast and ovarian cancer. It aims to see if personalized risk assessments affect their understanding and decisions about cancer prevention.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo genotyping with enhanced risk assessment and receive tailored counseling
Follow-up
Participants are monitored for satisfaction, decision-making, and outcomes after receiving risk assessments
Treatment Details
Interventions
- Enhanced Risk Assessments
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor